期刊文献+

骨化三醇注射液治疗血液透析患者难治继发性甲状旁腺功能亢进的临床观察 被引量:4

Clinical observation about Calcitriol injection curing refractory secondary hyperparathyroidism in hemodialysis patients
下载PDF
导出
摘要 目的观察骨化三醇注射液治疗骨化三醇胶囊口服无效的继发性甲状旁腺功能亢进(secondary hyperparathyroidism,SHPT)的疗效。方法选取石河子市人民医院2014年1月至2015年11月血液透析(hemodialysis,HD)的继发性甲状旁腺功能亢进的患者,选择其中对骨化三醇胶囊口服冲击无效的28例,给予骨化三醇注射液,比较治疗前及治疗后2、4、8周的全段甲状旁腺激素、血钙、血磷的变化及临床症状的缓解程度。结果 128例患者治疗前血清全段甲状旁腺激素(1186.7±305)pg/ml,治疗后8周血清全段甲状旁腺激素(506.2±146)pg/ml,总达标率87.1%。2血磷及血钙变化不大。3临床症状骨痛、皮肤瘙痒、四肢无力、关节痛有不同程度缓解。结论骨化三醇注射液在骨化三醇胶囊冲击无效的情况下,对继发性甲状旁腺功能亢进的患者依然有效。 Objective To observe the curative effect of calcitriol injection on secondary hyperparathyroidism when oral calcitriol capsule was invalid.Methods 28 cases of emodialysis patients with secondary hyperparathyroidism from January 2014 to November2015 who were proven to be invalid when taken orally calcitriol capsule were selected.All cases were given calcitriol injection.i PTH,blood calcium and blood phosphorus and relief of clinical symptoms before treatment and 2,4,8 weeks after treatment were compared.Results(1),i PTH in 28 patients before treatment were average 1186.7±305 pg/ml,while i PTH changed into 506.2±146 pg/ml at eight weeks after treatment,and the total control rate was 87.1%.(2) There were no obvious changes about values of blood phosphorus and calcium.(3) The clinical symptoms of bone pain,itchy skin,limb weakness,joint pain were relieved to different extent.Conclusion Injection of calcitriol is still valid to patients with secondary hyperparathyroidism when it is invalid if they are taken calcitriol capsule.
出处 《新疆医学》 2016年第7期800-802,共3页 Xinjiang Medical Journal
关键词 骨化三醇注射液 血液透析 继发性甲状旁腺功能亢进症 Calcitriol injection Hemodialysis Secondary hyperparathyroidism
  • 相关文献

参考文献7

二级参考文献25

  • 1顾勇,丁峰,陈楠,梅长林,钱家麒,王笑云,史伟,侯凡凡,李学旺,王梅,谌贻璞.阿法迪三~冲击和每日治疗对血液透析患者继发性甲旁亢疗效的随机多中心对照临床研究[J].中华肾脏病杂志,2004,20(5):315-320. 被引量:23
  • 2Chertow GM, Burke SK, Raggi P, et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients [J]. Kidney Int, 2002, 62(1): 245-252.
  • 3Bailie GR. Calcium and phosphorus management in chronic kidney disease: Challenges and trends[J]. Formulary, 2004, 39(7): 358-365.
  • 4National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease[J]. Am J Kidney Dis, 2003, 42(4 Suppl 3) :S1-S201.
  • 5Schomig M, Ritz E. Management of disturbed calcium metabolism in uraemic patients: 3. Potential perspectives-calcimimetics[J]. Nephrol Dial Transplant, 2000, 15(Suppl 5): 30-31.
  • 6Ito H,Ogata H,Yamamoto M,et al.Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism:a randomized,crossover trial[J].Clin Nephrol,2009,71:660-668.
  • 7National Kidney Foundation.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease[J].Am J Kidney Dis,2003,42:S1-201.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.Am J Kidney Dis.2003:42(4 Suppl 3):S1-201.
  • 8Levey AS,Coresh J,Balk E.et al.National Kidney Foundation practice guidelines for chronic kidney disease:evaluation,classification,and stratification[J].Ann Intern Med,2003,139:137-147.
  • 9Raggi P,Boulay A,Chasan-Taber S,et al.Cardiac calcification in adult hemodialysis patients.A link between end-stage renal disease and cardiovascular disease?[J].J AM COLL Cardiol,2002,39:695-701.
  • 10Andress DL,Norris KC,Coburn JW,et al.Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure[J].N Engl J Med,1989,321:274-279.

共引文献25

同被引文献42

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部